Status:
UNKNOWN
Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer
Lead Sponsor:
People's Hospital of Guangxi Zhuang Autonomous Region
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
Maintenance therapy has been considered as an important component to prolong survival in patients with advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC). Previous studies have confirmed that pem...
Eligibility Criteria
Inclusion
- Histologically or cytologically proven nonsquamous non-small cell lung cancer
- Stage IIIb-IV, according to AJCC 2010 Staging System
- Disease measurable
- Patients are currently receiving two-drug chemotherapy regimen containing a platinum-based drug as first-line therapy
- No chemotherapy or radiotherapy prior to first-line therapy
- Age between 18-75
- Performance status \<2
- No congestive heart failure, severe arrhythmia,and coronal atherosclerosis heart disease
- No uncontrolled metabolic disease, infection, and neurological disorders
- No other malignancies
- Signed study-specific consent form prior to study entry
Exclusion
- Patients are currently receiving radiotherapy or any chemotherapy regimen other than two-drug containing a platinum-based drug as first-line therapy
- Pregnant or lactating women
- Patient having hepatitis B virus infection, active tuberculosis, or other infectious diseases
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT01481259
Start Date
January 1 2010
End Date
July 1 2013
Last Update
July 3 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Cancer Center, People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China, 530021